ChickenStockChickenStock

AI English summary of an SEC filing — figures as filed

Bio-Techne logoBio-Techne TECH

Bio-Techne said Dr. Matt McManus, President of its Diagnostics and Spatial Biology Segment, will transition from his role effective March 1, 2026 and will remain with the company for a period of time to support a smooth transition.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary

  1. Bio-Techne said Dr. Matt McManus, President of its Diagnostics and Spatial Biology Segment, will transition from his role effective March 1, 2026 and will remain with the company for a period of time to support a smooth transition.

  2. The company said it appointed Steve Crouse, age 52, as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Crouse currently serves as Senior Vice President of Bio-Techne's Analytical Solutions Division and previously served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit.

  3. Bio-Techne said Crouse's employment agreement, entered into on February 10, 2026, provides for an annual base salary of $505,000 and an annual cash incentive bonus at a target amount of 75% of his base salary. The agreement commences on March 1, 2026.

  4. The company said it provided Crouse with annual equity awards consisting of time-vested stock options with a grant date value of approximately $300,000, time-vested restricted stock units with a grant date value of approximately $300,000, and performance-based restricted stock units with a grant date value of $600,000 at target. In the event of termination by the company without Cause or other specified circumstances, the company will pay severance equal to 1 year of his then-current base salary, a prorated portion of annual cash incentive compensation, and health insurance coverage for one year.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Diagnostics and Spatial Biology Segment President Transition

Bio-Techne said Dr. Matt McManus, President of its Diagnostics and Spatial Biology Segment, will transition from his role effective March 1, 2026 and will remain with the company for a period of time to support a smooth transition.

Source · Based on the filing body and exhibits

Steve Crouse Appointed President; Background

The company said it appointed Steve Crouse, age 52, as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Crouse currently serves as Senior Vice President of Bio-Techne's Analytical Solutions Division and previously served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit.

Source · Based on the filing body and exhibits

Steve Crouse Employment Agreement Compensation Terms

Bio-Techne said Crouse's employment agreement, entered into on February 10, 2026, provides for an annual base salary of $505,000 and an annual cash incentive bonus at a target amount of 75% of his base salary. The agreement commences on March 1, 2026.

Source · Based on the filing body and exhibits

Steve Crouse Equity Awards and Severance Provisions

The company said it provided Crouse with annual equity awards consisting of time-vested stock options with a grant date value of approximately $300,000, time-vested restricted stock units with a grant date value of approximately $300,000, and performance-based restricted stock units with a grant date value of $600,000 at target. In the event of termination by the company without Cause or other specified circumstances, the company will pay severance equal to 1 year of his then-current base salary, a prorated portion of annual cash incentive compensation, and health insurance coverage for one year.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.